Navigation Links
Octapharma USA Retains Yankee Public Relations as its Agency of Record
Date:10/6/2008

Octapharma USA, a subsidiary of the largest privately owned plasma products company in the world, has selected Yankee Public Relations of Alexandria Township, N.J. as its public relations firm of record.

Hoboken, NJ (PRWEB) October 6, 2008 -- Octapharma USA, a subsidiary of the largest privately owned plasma products company in the world, has selected Yankee Public Relations of Alexandria Township, N.J. as its public relations firm of record.

"This year marks Octapharma's 25th anniversary and we are expecting tremendous growth in the very near future," said Octapharma USA President Flemming Nielsen. "Having seasoned, creative public relations talent behind us is vitally important to our company's business objectives. Fred Feiner and Yankee PR will be a tremendous asset as our company continues to grow."

Based in Lachen, Switzerland, Octapharma is responsible for the development, production and sale of high quality, virus safe plasma derivatives, including intravenous immunoglobulin (IVIG). In the U.S., Octapharma's IVIG product, octagam®, is used to treat disorders of the immune system and Octapharma's Albumin (Human) 5% is indicated for the restoration and maintenance of circulating blood volume.

"It is an outstanding opportunity to represent Octapharma USA at this important time in the company's history," said Yankee PR President Fred Feiner. "Even during a difficult business cycle for the pharmaceutical industry, Octapharma is thriving with sales continuing to outpace their competition. Demand for Octapharma products continues to build and significant U.S. growth is expected so it is a great time to be building the company's brand."

The Yankee PR team has over 20 years of experience in media relations, marketing communications and crisis management with particular expertise in the pharmaceutical, real estate and finance industries. Feiner's clients have included some of the largest development companies and investment funds on the East Coast, as well as leading-edge architecture, engineering and technology firms. For more information on the firm, please call 908-894-3930 or visit them at www.yankeepr.com.

Octapharma
Octapharma is the largest privately owned plasma fractionation company in the world. Its core business is the development, production and sale of high quality, virus safe plasma derivatives, including intravenous immunoglobulin (IVIG). From its foundation in 1983, the Swiss-based company has grown to employ over 2000 people in 27 countries, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma owns four modern, state-of-the-art production facilities in Vienna, Austria; Strasbourg, France; Stockholm, Sweden; and Mexico City, Mexico; and also operates a fifth fractionation facility in Springe, Germany. For more information, please visit www.octapharma.com or call 201-604-1130.

###

Read the full story at http://www.prweb.com/releases/octapharma/pharmaceutical/prweb1423854.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
2. Octapharma Joins Biotechnology Industry Organization
3. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
4. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
5. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. Dragon retains leading investor relations firm
10. Interleukin Genetics Retains Top Life Science Communications Firms
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Octapharma USA Retains Yankee Public Relations as its Agency of Record 
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced ... I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking ... update on the phase I/II clinical trials for AC0010 in patients with advanced non-small ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced ... days and will take place on February 1-3, 2017 at the Roosevelt Hotel in ... (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information ...
(Date:12/2/2016)... ... 2016 , ... Robots will storm the Prudential Center in Boston, MA during ... which is held on the United Nations International Day of Persons with Disabilities, will ... workplace. Suitable Technologies is partnering with NTI to showcase how technology can help individuals ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand of ... flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. The ... where extreme precision is required, such as in medical equipment, laboratory instrumentation, clean ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):